MGlu receptors as potential targets for novel antidepressants. (February 2018)

• Record Type: Journal Article
• Authors: Chaki, Shigeyuki; Fukumoto, Kenichi
• Is Part Of: Current opinion in pharmacology. Volume 38(2018)
• Page Start: 24
• Page End: 30
• Publication Date: 2018-02
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2018.02.001
• Languages: English
• ISSNs: 1471-4892

Abstract

Highlights: mGlu2/3 antagonists exert ketamine-like antidepressant effects in rodent models. mGlu2/3 antagonists shared some of their mechanisms with ketamine. mGlu5 NAMs exert antidepressant effects in rodent models. The mechanisms of mGlu5 NAMs may differ from those of ketamine. Antidepressant potential of group III mGlu ligands need to be further investigated. Abstract : Ever since the discovery of the rapid and sustained antidepressant effect of ketamine, a non-competitive N -methyl-d -aspartate receptor antagonist, agents acting on the glutamatergic system have been explored for their potential as novel antidepressants. Among the glutamategic system, metabotropic glutamate (mGlu) receptors, which play important roles in regulating glutamate transmission, have recently gained much attention as potential targets for the development of novel antidepressants. Of these, the antidepressant effects of agents acting on the mGlu2/3 receptor and mGlu5 receptor have been well characterized in several animal models. Moreover, the synaptic and neural mechanisms underlying the antidepressant actions of mGlu2/3 receptor and mGlu5 receptor antagonists have been elucidated, in comparison with those of ketamine. In contrast, the roles of the group III mGlu receptors, including mGlu4 and mGlu7, in depression remain to be investigated further by using selective ligands for each receptor.